Will Parsons: This is a fantastic opportunity to test precision oncology for pediatric patients in a large-scale way

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

New pressures notwithstanding, being a cancer center director is still a dream job, two of the nation’s newest cancer center directors said.

August 07, 2026

Vol.52 No.31

By Claire Marie Porter and Paul Goldberg

Regulatory News

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

August 07, 2026

Vol.52 No.31

By Jacquelyn Cobb and Paul Goldberg

Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup

U.S. News & World Report has been publishing the best cancer hospitals rankings for 37 years, but this year is different.

August 07, 2026

Vol.52 No.31

By Sara Willa Ernst

Clinical Guest Editorial

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

A patient recently asked me a question I suspect many thoracic surgeons will soon be hearing.

August 07, 2026

Vol.52 No.31

By Raja Flores

Data-driven: Using AI to solve the complexities of cancer

When it comes to harnessing artificial intelligence for cancer breakthroughs, Johns Hopkins researchers Alex Szalay, PhD, and Janis Taube, MD, MSc, believe the future begins with data—lots of it.

August 07, 2026

Vol.52 No.31

By Johns Hopkins Kimmel Cancer Center Communications

Cancer Policy

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

The Senate has released its version of a 2027 continuing resolution that would fund the U.S. government through Dec. 11.

August 07, 2026

Vol.52 No.31

By Jacquelyn Cobb

Will Parsons: This is a fantastic opportunity to test precision oncology for pediatric patients in a large-scale way

YOU MAY BE INTERESTED IN

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

Data-driven: Using AI to solve the complexities of cancer

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

Renew today!

Subscriber content

Never miss an issue!

Login

Will Parsons: This is a fantastic opportunity to test precision oncology for pediatric patients in a large-scale way

YOU MAY BE INTERESTED IN

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committeeAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots2026 report shows no change in the top-five lineup

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

Data-driven: Using AI to solve the complexities of cancer

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

Never miss an issue!

Login

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial

Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup